首页> 美国卫生研究院文献>Diabetes Therapy >Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM
【2h】

Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM

机译:与1型糖尿病相比1型糖尿病(T1DM)的较低的肾脏重吸收葡萄糖阈值可能说明SGLT2抑制剂对改善血浆葡萄糖控制的贡献较小

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

IntroductionPreviously, we reported that the renal threshold for glucose reabsorption can be measured as the lowest plasma glucose level that correlates with the first detectable appearance of urine glucose. These data revealed significant variations among patients with type 2 diabetes mellitus (T2DM), and there was a significant negative correlation between the renal threshold for glucose reabsorption and HbA1c levels following treatment with the sodium-glucose co-transporter 2 (SGLT2) inhibitor ipragliflozin. Recently approved SGLT inhibitors may not show the same efficacy in patients with T1DM as in those with T2DM unless the renal threshold for glucose reabsorption shows similar levels between the two groups. SGLT2 inhibitors improve plasma glucose control in patients with T2DM by reducing glucose reabsorption via the epithelial cells of the proximal tubule.
机译:引言先前,我们报道了肾脏的葡萄糖重吸收阈值可以通过与可检测到的尿糖首次出现相关的最低血浆葡萄糖水平进行测量。这些数据显示2型糖尿病(T2DM)患者之间存在显着差异,并且在使用钠-葡萄糖共转运蛋白2(SGLT2)抑制剂依普列净治疗后,肾脏的葡萄糖重吸收阈值与HbA1c水平之间呈显着负相关。除非肾再吸收阈值显示两组之间相似的水平,否则最近批准的SGLT抑制剂在T1DM患者中可能不会显示出与T2DM患者相同的疗效。 SGLT2抑制剂可通过减少近端小管上皮细胞的葡萄糖重吸收来改善T2DM患者的血糖控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号